Details for Patent: 10,973,934
✉ Email this page to a colleague
Which drugs does patent 10,973,934 protect, and when does it expire?
Patent 10,973,934 protects ELUCIREM and is included in one NDA.
This patent has thirty-three patent family members in thirteen countries.
Summary for Patent: 10,973,934
| Title: | Gadolinium bearing PCTA-based contrast agents |
| Abstract: | The present invention relates to the RRR/SSS pair of enantiomers of the of Gd(PCTA-tris-glutaric acid), the single enantiomers of the pair, the pharmaceutically acceptable salts thereof, their amide derivatives, and compositions comprising at least 50% of these compounds. |
| Inventor(s): | Roberta Napolitano, Luciano Lattuada, Zsolt BARANYAI, Nicole GUIDOLIN, Giuseppe Marazzi |
| Assignee: | Bracco Imaging SpA |
| Application Number: | US16/766,619 |
|
Patent Claim Types: see list of patent claims | Composition; Compound; |
Drugs Protected by US Patent 10,973,934
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Guerbet | ELUCIREM | gadopiclenol | SOLUTION;INTRAVENOUS | 216986-001 | Sep 21, 2022 | RX | Yes | Yes | 10,973,934 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Guerbet | ELUCIREM | gadopiclenol | SOLUTION;INTRAVENOUS | 216986-002 | Sep 21, 2022 | RX | Yes | Yes | 10,973,934 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Guerbet | ELUCIREM | gadopiclenol | SOLUTION;INTRAVENOUS | 216986-003 | Sep 21, 2022 | RX | Yes | Yes | 10,973,934 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Guerbet | ELUCIREM | gadopiclenol | SOLUTION;INTRAVENOUS | 216986-004 | Sep 21, 2022 | RX | Yes | Yes | 10,973,934 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Guerbet | ELUCIREM | gadopiclenol | SOLUTION;INTRAVENOUS | 216986-005 | Sep 21, 2022 | RX | Yes | Yes | 10,973,934 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Guerbet | ELUCIREM | gadopiclenol | SOLUTION;INTRAVENOUS | 216986-006 | Sep 21, 2022 | RX | Yes | Yes | 10,973,934 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Guerbet | ELUCIREM | gadopiclenol | SOLUTION;INTRAVENOUS | 216986-007 | Sep 21, 2022 | RX | Yes | Yes | 10,973,934 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,973,934
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2019319599 | ⤷ Start Trial | |||
| Brazil | 112021001102 | ⤷ Start Trial | |||
| Canada | 3105610 | ⤷ Start Trial | |||
| China | 112533921 | ⤷ Start Trial | |||
| China | 119039292 | ⤷ Start Trial | |||
| China | 119930615 | ⤷ Start Trial | |||
| China | 119954806 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
